This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Objective To investigate temporal trends of chronic kidney disease (CKD) among patients with incident aortic stenosis (AS) and to compare these trends with that of a matched control population. The predialysis subgroup had at least one hospital or two billing diagnostic codes of CKD. Three subgroups were considered.
With more than two decades of research experience, Boden-Albala is an internationally recognized expert in the social epidemiology of chronicdisease whose research has focused on eliminating health disparities through defining and intervening on social support, structural and institutional barriers to optimal health. Chimowitz, M.B.,
Meta-Analysis Evidence : A meta-analysis of five heart failure (HF) trials demonstrated significant reductions in cardiovascular deaths and first heart failure hospitalizations. CKD Outcomes: SGLT2 inhibitors reduce kidney disease progression by 38% in dedicated trials, benefiting a wide range of CKD patients.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Chronic Disease 
52 
Let's personalize your content